Thalidomide-O-amido-PEG2-C2-NH2 (TFA)
Catalog No. A21634
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
Catalog Num | A21634 |
---|---|
M. Wt | 576.48 |
Formula | C23H27F3N4O10 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 1957235-75-4 |
Synonyms | Cereblon Ligand-Linker Conjugates 10 (TFA); E3 Ligase Ligand-Linker Conjugates 24 (TFA) |
SMILES | O=C(NCCOCCOCCN)COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O.O=C(O)C(F)(F)F |
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 17.35 mL | 86.73 mL | 173.47 mL |
0.5 mM | 3.47 mL | 17.35 mL | 34.69 mL |
1 mM | 1.73 mL | 8.67 mL | 17.35 mL |
5 mM | 0.35 mL | 1.73 mL | 3.47 mL |
*The above data is based on the productmolecular weight 576.48. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.